Fisher & Paykel Healthcare

Inspired and world-leading healthcare solutions

DEUTSCHE BANK CRAIGS NZ COMPANIES DAY | Sydney, 8 March 2016
Investment Highlights

- A leader in respiratory and OSA treatment devices
- Consistent growth strategy
- Estimated US$5.0+ billion and growing market opportunity
- High level of innovation
- Global presence
- Strong financial performance
  NZSX:FPH, ASX:FPH
Market Opportunity and Patient Groups

**RESPIRATORY & ACUTE CARE / HOSPITAL**
- Invasive Ventilation
- Noninvasive Ventilation
- Hospital Respiratory Support

**OBSTRUCTIVE SLEEP APNEA / HOMECARE**
- Surgical Humidification
- Home Respiratory Support
- CPAP Therapy

“NEW APPLICATIONS”
Applications outside of invasive ventilation
Markets & Products

- Respiratory & Acute Care / Hospital (RAC)
  - Heated humidification
  - Respiratory care
  - Neonatal care
  - Surgery

- Obstructive Sleep Apnea / Homecare (OSA)
  - Masks
  - Flow generators
  - Data management tools
  - Humidifiers

Recurring items, consumables and accessories approximately 83% of operating revenue (H1 FY15: 80%)
Hospital Cost Breakdown

94% Other – includes labour, utilities, drugs, supplies, food, depreciation.

6% Medical devices

Source: Estimates of Medical Device Spending in the United States, Donahoe, G and King, G, June 2014
Lower Care Intensity = Lower Cost

Mean Annual COPD-Related Medical, Pharmacy, and Total Costs by Care Intensity Cohort

Respiratory & Acute Care / Hospital (RAC)

**Invasive Ventilation**

**Noninvasive Ventilation**

**Hospital Respiratory Support**

**Surgical Humidification**

“NEW APPLICATIONS”
Applications outside of invasive ventilation
Normal airway humidification is bypassed or compromised during ventilation or oxygen therapy.

Mucociliary transport system operates less effectively.

Need to deliver gas at physiologically normal levels:
- 37°C body core temperature
- 44mg/L 100% saturated
Respiratory, Acute Care & Surgical - Hardware

- **850 respiratory humidifier system**
  - Invasive ventilation, oxygen therapy and non-invasive ventilation

- **810 respiratory humidifier system**
  - Entry level system
  - Ventilation and oxygen therapy
  - Optional heated breathing circuit

- **AIRVO 2 flow generator/humidifier**
  - Optiflow oxygen therapy
  - Humidity therapy

- **HumiGard surgical humidifier**
  - Laparoscopic insufflation
  - Open surgery
Respiratory & Acute Care - Single Use Consumables

- Single-use chambers
  - Patented auto filling MR290

- Single-use breathing circuits
  - Patented spiral heater wire
  - Proprietary Evaqua 2 expiratory tube
  - Minimal condensation
  - Delivery of optimal humidity

- Breathing circuit components
  - Filters, catheter mount, weaning kit

- Interfaces
  - NIV masks, tracheostomy, Optiflow nasal cannula

- Approx 30 system set-ups used per controller per year

- Consumable growth driving revenue growth
Optiflow™ Therapy – Delivery Options

F&P 850™ System

F&P AIRVO™ 2
Obstructive Sleep Apnea / Homecare (OSA)

Home Respiratory Support

CPAP Therapy
Obstructive Sleep Apnea

- Temporary closure of airway during sleep
- Can greatly impair quality of sleep, leading to fatigue; also associated with hypertension, stroke and heart attack
- Estimated US$3+ billion worldwide market, growing approximately 6 - 8%
- Estimate >50 million people affected in developed countries
- Most common treatment is CPAP (Continuous Positive Airway Pressure)
  - Key issue with CPAP is compliance
  - Humidification provides significant acceptance and compliance improvements
Revolutionary Masks

- Market leading mask technology
- Unique, patented designs
- Mask Matters Most
  - Masks are key to compliance

F&P ESON 2  F&P SIMPLUS  F&P PILAIRO Q
Stylish, Smart + Simplified CPAP Range

- Efficiently integrates with InfoUSB and InfoSmart Web
- Responsive pressure relief - SensAwake
- ThermoSmart humidifier breathing tube technology
- Auto-adjusting CPAP
Efficient Compliance Reporting
Research & Development

- 9.4% of operating revenue, NZ$35.8M\(^1\)
- Product pipeline includes:
  - Humidifier controllers
  - Masks
  - Respiratory consumables
  - Flow generators
  - Compliance monitoring solutions
- 125 US patents, 314 US pending, 513 ROW, 471 ROW pending\(^2\)

---

\(^1\) 6 months to 30 September 2015
\(^2\) as at 30 September 2015
Manufacturing & Operations

- Vertically integrated
  - COGs improvements; Mexico, Lean manufacturing, supply chain

- Ample capacity to grow

**Auckland, New Zealand**
- Three buildings: 82,000 m² / 885,000 ft² total
- 100 acres/40ha land

**Tijuana, Mexico**
- 18,000 m² / 200,000 ft²
- Manufacturing floor area increased by 66%
- Consumables capacity ramping up
Global Presence

- Direct/offices
  - Hospitals, home care dealers
  - Sales/support offices in North America, Europe, Asia, South America, Middle East and Australasia, 15 distribution centres
  - More than 600 staff in 30 countries
  - Ongoing international expansion

- Distributors
  - 100+ distributors worldwide

- Original Equipment Manufacturers
  - Supply most leading ventilator manufacturers
  - More than 120 countries in total

Revenue by Region
6 months to 30 September 2015

- North America: 46%
- Europe: 30%
- Asia Pacific: 19%
- Other: 5%
First Half Result Highlights

**H1 FY2016** (6 months to 30 September 2015)

<table>
<thead>
<tr>
<th></th>
<th>NZ$M</th>
<th>△ PCP</th>
<th>△ CC&lt;sup&gt;1&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Record net profit after tax</td>
<td>62.0</td>
<td>+27%</td>
<td>+25%</td>
</tr>
<tr>
<td>Record operating revenue</td>
<td>381.0</td>
<td>+20%</td>
<td>+12%</td>
</tr>
<tr>
<td>Record RAC/Hospital operating revenue</td>
<td>199.6</td>
<td>+18%</td>
<td>+11%</td>
</tr>
<tr>
<td>Record OSA/Homecare operating revenue</td>
<td>175.3</td>
<td>+23%</td>
<td>+14%</td>
</tr>
<tr>
<td>RAC new applications consumables revenue</td>
<td></td>
<td>+30%</td>
<td>+22%</td>
</tr>
<tr>
<td>OSA masks revenue</td>
<td></td>
<td>+35%</td>
<td>+25%</td>
</tr>
<tr>
<td>Gross margin (bps increase)</td>
<td></td>
<td>+276bps</td>
<td>+348bps</td>
</tr>
</tbody>
</table>

Recurring items, consumables and accessories approximately 83% of operating revenue (H1 FY15: 80%)

<sup>1</sup> *CC = constant currency*
Innovative New Products Launched

F&P Eson™ 2 nasal mask

Optiflow™ + nasal high flow cannula

AirSpiral tube and uninterruptible power supply (UPS) transport system for AIRVO™2

F&P HumiGard™ SH870 surgical humidification system
### H1 FY2016 Operating Results

#### H1 FY2016 (6 months to 30 September 2015)

<table>
<thead>
<tr>
<th></th>
<th>% of Revenue</th>
<th>NZ$M</th>
<th>△ PCP</th>
<th>△ CC¹</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Operating revenue</strong></td>
<td>100.0%</td>
<td>381.0</td>
<td>+20%</td>
<td>+12%</td>
</tr>
<tr>
<td><strong>Cost of sales</strong></td>
<td>36.7%</td>
<td>139.8</td>
<td>+12%</td>
<td>+3%</td>
</tr>
<tr>
<td><strong>Gross profit</strong></td>
<td>63.3%</td>
<td>241.2</td>
<td>+25%</td>
<td>+19%</td>
</tr>
<tr>
<td><strong>Other income (R&amp;D grant)</strong></td>
<td>2.5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SG&amp;A</strong></td>
<td>29.6%</td>
<td>112.7</td>
<td>+24%</td>
<td>+17%</td>
</tr>
<tr>
<td><strong>R&amp;D</strong></td>
<td>9.4%</td>
<td>35.8</td>
<td>+14%</td>
<td>+14%</td>
</tr>
<tr>
<td><strong>Total operating expenses</strong></td>
<td>39.0%</td>
<td>148.5</td>
<td>+22%</td>
<td>+16%</td>
</tr>
<tr>
<td><strong>Operating profit</strong></td>
<td>25.0%</td>
<td>95.2</td>
<td>+31%</td>
<td>+25%</td>
</tr>
<tr>
<td><strong>Profit after tax</strong></td>
<td>16.3%</td>
<td>62.0</td>
<td>+27%</td>
<td>+25%</td>
</tr>
</tbody>
</table>

1. **CC = constant currency**
Increased interim dividend by 16%:

- 6.7 cps + 2.6056 cps imputation credit for NZ residents (gross dividend of 9.3056 NZ cps)
- Fully imputed
- 1.1824 cps non-resident supplementary dividend
- Dividend reinvestment plan available for New Zealand and Australian residents, no discount will apply

Gearing ratio* target of +5% to -5% debt to debt plus equity

- Gearing ratio at 30 September 2015 was 17%

* Calculated using net interest bearing liabilities to total equity excluding unrealised financial instrument gains or losses
## Respiratory & Acute Care / Hospital (RAC)

<table>
<thead>
<tr>
<th>Operating revenue growth</th>
<th>H1 FY2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>NZ$</td>
<td>+18%</td>
</tr>
<tr>
<td>Constant currency</td>
<td>+11%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>New applications consumables revenue growth</th>
<th>H1 FY2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>(Noninvasive ventilation (NIV), Optiflow, AIRVO, Surgical)</td>
<td></td>
</tr>
<tr>
<td>NZ$</td>
<td>+30%</td>
</tr>
<tr>
<td>Constant currency</td>
<td>+22%</td>
</tr>
</tbody>
</table>

- New applications consumables now make up 48% of RAC consumables revenue, up from 45% in H1 FY2015

**Further positive clinical trial results:**
- Optiflow resulted in a similar rate of reintubation as NIV (Hernandez et al 2015)
- Use of HumiGard during colorectal surgery can reduce surgical site infections (Noor et al 2015)
<table>
<thead>
<tr>
<th></th>
<th>Operating revenue growth</th>
<th>H1 FY2016</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>NZ$</td>
<td>+23%</td>
</tr>
<tr>
<td></td>
<td>Constant currency</td>
<td>+14%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Mask revenue growth</th>
<th>H1 FY2016</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Constant currency</td>
</tr>
</tbody>
</table>

- Masks continue to take market share
### Cash Flow & Balance Sheet

**1H FY2016 (for the 6 months ended 30 September 2015)**

<table>
<thead>
<tr>
<th>Description</th>
<th>NZ$M</th>
</tr>
</thead>
<tbody>
<tr>
<td>Operating cash flow (-37%)</td>
<td>35.2</td>
</tr>
<tr>
<td>Capital expenditure</td>
<td>36.2</td>
</tr>
<tr>
<td>Depreciation and amortisation</td>
<td>16.9</td>
</tr>
</tbody>
</table>

**1H FY2016 (as at 30 September 2015)**

<table>
<thead>
<tr>
<th>Description</th>
<th>NZ$M</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net debt</td>
<td>97.4</td>
</tr>
<tr>
<td>Total shareholders equity</td>
<td>447.8</td>
</tr>
<tr>
<td>Total assets</td>
<td>735.2</td>
</tr>
</tbody>
</table>

**Pre-tax return on equity (annualised)**: 37%

**Pre-tax return on total assets (annualised)**: 24%

**Gearing (debt/debt to equity)**: 17%
Foreign Exchange Effects

- 51% of operating revenue in USD (1H FY15: 47%) and 21% in €.
- Approximately 45% of the NZD/USD hedging in place for FY17 is in the form of collar options. The average exchange rates resulting from the collar options will vary depending on the spot rate at their expiries.

<table>
<thead>
<tr>
<th>Hedging position for our main exposures</th>
<th>2016</th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>USD % cover of expected exposure</td>
<td>96%</td>
<td>74%</td>
<td>39%</td>
<td>23%</td>
<td>21%</td>
<td>17%</td>
</tr>
<tr>
<td>USD average rate of cover</td>
<td>0.725</td>
<td>0.687</td>
<td>0.659</td>
<td>0.643</td>
<td>0.626</td>
<td>0.614</td>
</tr>
<tr>
<td>EUR % cover of expected exposure</td>
<td>96%</td>
<td>77%</td>
<td>43%</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>EUR average rate of cover</td>
<td>0.580</td>
<td>0.576</td>
<td>0.577</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Year to 31 March
Consistent Growth Strategy

- Improving care and outcomes
- Reducing cost to the healthcare system

**Increase**
- Effectiveness of care
- Efficiency of care

**Reduce**
- Intensity of care
- Healthcare system cost

**Four key pillars:**
- Continuous product improvement
- More devices for each patient
- Serve more patient groups
- Increase international presence